

**29 October 2018**

**To, BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001

Scrip Code: 524669

**To, National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra - Kurla Complex,  
Bandra (E), Mumbai - 400 051

Symbol: HESTERBIO

**Respected Sir / Madam,**

**Subject: Outcome of Board Meeting held today and Submission of Unaudited Standalone Financial Results for the quarter and half year ended on 30 September 2018**

**Start Time: 10.45 am**

**Conclusion Time: 11.02 am**

This is in reference to our letter dated 17 October 2018 intimating the date of the Board Meeting for consideration of the Unaudited Standalone Financial Results for the quarter and half year ended on 30 September 2018.

Pursuant to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that Board of Directors, in their Meeting held today, have approved the followings:

1. Unaudited Standalone Financial Results for the quarter and half year ended on 30 September 2018.
2. The Board of Directors declared 2nd interim dividend of 20% that is INR 2.00 (two) per equity share on the face value of INR 10 (ten) per share. The Company has already paid 1st Interim Dividend of INR 2.00 (Two) per equity shares.
3. Revision in remuneration of Mr. Rajiv Gandhi, CEO & Managing Director of the Company for the current tenure ending on 31 March 2020, subject to approval of Members.

We attach herewith:

- 1) The approved Unaudited Standalone Financial Results under Regulations 33 of SEBI (LODR) Regulations, 2015 and Limited Review Report from Auditors.
- 2) Press Release issued in this regard

We are arranging to publish these results in the newspaper as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take the above information on your record.

**Sincerely,  
For Hester Biosciences Limited**



**Rajiv Gandhi**  
**CEO & Managing Director**  
DIN: 00438037